In various cancer cells, STL427944 was efficiently blocking FOXM1 activity, providing a completely new mode of action; however, due to some metabolic liabilities, it worked at concentrations that are considered too high for a targeted inhibitor [5]. This evidence concerns the gene FOXM1 and cancer.